P047The Crohn's Disease-Health Index (CD-HI): Development and Validation of a Novel, Disease-Specific Patient

Jamison Seabury1, Jennifer Weinstein1, Spencer Rosero1

  • 1Center for Health + Technology, Rochester, Minnesota, United States.

Insights

The Crohn's Disease-Health Index (CD-HI) is a new patient-reported outcome measure (PROM) that is valid and reliable for assessing Crohn's disease (CD) burden. This tool helps track how CD patients feel and function, aiding clinical trial research.

Area of Science:

  • Gastroenterology
  • Clinical Research
  • Patient-Reported Outcomes

Background:

  • Crohn's disease (CD) management requires reliable tools to measure patient-reported outcomes (PROMs).
  • The Crohn's Disease-Health Index (CD-HI) was developed to quantify symptomatic disease burden in CD patients for clinical trials.
  • A validated, sensitive, and reliable PROM is crucial for evaluating therapeutic interventions in CD.

Purpose of the Study:

  • To develop and validate the Crohn's Disease-Health Index (CD-HI).
  • To assess the validity, reliability, and usability of the CD-HI as a disease-specific PROM for CD.
  • To provide a tool for quantifying CD patient experience and function in clinical research.

Main Methods:

  • Qualitative interviews with CD patients to identify key symptoms.
  • Cross-sectional survey to determine symptom prevalence and importance.
  • Factor analysis for subscale development, beta testing for usability, and test-retest reliability assessments.

Main Results:

  • The final CD-HI includes 12 subscales covering fatigue, diet, GI health, sleep, bowel/bladder function, emotional health, joint health, pain, back/neck health, activity, social health, and skin health.
  • Patients found the CD-HI clear, relevant, and easy to use.
  • The instrument demonstrated good validity, reliability, and internal consistency for measuring CD disease burden.

Conclusions:

  • The CD-HI is a valid and reliable disease-specific PROM for CD.
  • It effectively captures patient-relevant data on how CD patients feel and function.
  • The CD-HI offers an optimal tool for researchers and clinicians to track CD health changes from the patient's perspective.
Abstract

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
298
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
198
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
155
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
489